MORRISTOWN, NJ, Sep 08, 2009 (MARKETWIRE via COMTEX) -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty
pharmaceutical company, today announced that Paul Bisaro, Watson's
president and chief executive officer, will provide an overview and
update of the Company's business at the Bank of America Merrill Lynch
Global Healthcare Conference on Tuesday, September 15, 2009 at 2:30
p.m. (BST) (9:30 a.m. EDT).
This presentation will be webcast live and can be accessed on Watson
Investor Relations Web site at http://ir.watson.com.
The webcast can also be accessed at the following URL:
An archived version will be available for 30 days after the live
presentation and can be accessed at the same locations.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is a global leader in the development
and distribution of pharmaceuticals with a broad portfolio of generic
products and a specialized portfolio of brand pharmaceuticals focused
on Urology, Women's Health and Nephrology/Medical. For press release
and other company information, visit Watson Pharmaceuticals' Web site
Any statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Watson's current perspective of existing trends and
information as of the date of this release. Except as expressly
required by law, Watson disclaims any intent or obligation to update
these forward-looking statements. Actual results may differ
materially from Watson's current expectations depending upon a number
of factors affecting Watson's business. These factors include, among
others, the impact of competitive products and pricing; market
acceptance of and continued demand for Watson's products;
difficulties or delays in manufacturing; the difficulty of predicting
the timing or outcome of FDA or other regulatory agency approvals or
actions, if any; and other risks and uncertainties detailed in
Watson's periodic public filings with the Securities and Exchange
Commission, including but not limited to Watson's Quarterly Report on
Form 10-Q for the period ended June 30, 2009.
Watson Pharmaceuticals, Inc.
SOURCE: Watson Pharmaceuticals